Morgan Stanley Rates Disc Medicine (IRON) "Overweight" With $85 PT

Disc Medicine, Inc. (NASDAQ: IRON) receives an “Overweight” rating and $85 price target from Morgan Stanley. Bitopertin’s accelerated approval process and pipeline programs like DISC-0974 are highlighted for potential. The company’s APOLLO trial for EPP treatment is underway, with strong financials supporting future development. Cash balance stands at $694.7 million as of March 31, 2025.

While IRON shows investment potential, other AI stocks may offer greater upside and lower risk. An AI stock with undervalued potential in the wake of Trump-era tariffs is recommended. For more insights on AI stocks, check out reports on cheap AI stocks and unstoppable growth stocks. Disclosure: None. Originally published on Insider Monkey.

Read more at Yahoo Finance: Morgan Stanley Assumes Coverage of Disc Medicine (IRON) With $85 PT